ReviewBioImpacts : BI2026
Role of four new blood coagulation tests in cancer stem cell-mediated tumor-related venous thromboembolism.
Review in BioImpacts : BI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer often have a marked hypercoagulable state, which significantly raises the risk of thrombosis. Recent studies have shown that cancer stem cells (CSCs) play a crucial role in creating this prothrombotic environment by influencing the coagulation cascade and triggering thromboinflammation. This review comprehensively examines the role of four novel blood coagulation tests - thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2-antiplasmin complex (PIC), and tissue-type plasminogen activator-inhibitor 1 complex (t-PAIC) - in the context of cancer stem cell-mediated tumor-related venous thromboembolism (VTE). These markers offer distinct advantages over traditional coagulation assays for dynamic monitoring of coagulation and fibrinolysis in cancer-associated VTE, providing a more nuanced assessment of patient status. We elucidate the predictive, diagnostic, and risk-assessment value of this "four-item test," exploring its potential to identify patients at high risk of VTE and to monitor treatment efficacy. Furthermore, we delve into the underlying pathophysiological links connecting CSC activity, cancer-associated thrombosis (CAT), thromboinflammation, and the formation of neutrophil extracellular traps (NETs), suggesting that these biomarkers may offer valuable insights into the mechanisms driving thrombosis in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.